Abstract
Crohns disease and ulcerative colitis are the two principal forms of inflammatory bowel disease (IBD). The root causes of these chronic and acute immunological disorders are unclear, but intestinal microorganisms are known to play a key role in the initiation and maintenance of disease. However, at present, there is no clear evidence for a single transmissible agent being involved in IBD aetiology. Although marked alterations occur in faecal and mucosal bacterial communities in IBD, it is unclear whether they are responsible for causing disease, or are due to changes in the gut environment that result from inflammatory reactions and extensive tissue destruction. Despite the involvement of microorganisms in inflammatory processes, antibiotic therapy has generally been unsuccessful in IBD. However, recent studies involving the use of probiotics, prebiotics and synbiotics suggest that there is potential for controlling these diseases through manipulation of the composition of the gut microbiota, and direct interactions with the gut immune system.
Keywords: Inflammatory bowel disease, ulcerative colitis, Crohn's disease, gut microbiota, probiotics, prebiotics, synbiotics, sulphur metabolism
Current Pharmaceutical Design
Title: The Gut Microbiota in Inflammatory Bowel Disease
Volume: 15 Issue: 13
Author(s): G. T. Macfarlane, K. L. Blackett, T. Nakayama, H. Steed and S. Macfarlane
Affiliation:
Keywords: Inflammatory bowel disease, ulcerative colitis, Crohn's disease, gut microbiota, probiotics, prebiotics, synbiotics, sulphur metabolism
Abstract: Crohns disease and ulcerative colitis are the two principal forms of inflammatory bowel disease (IBD). The root causes of these chronic and acute immunological disorders are unclear, but intestinal microorganisms are known to play a key role in the initiation and maintenance of disease. However, at present, there is no clear evidence for a single transmissible agent being involved in IBD aetiology. Although marked alterations occur in faecal and mucosal bacterial communities in IBD, it is unclear whether they are responsible for causing disease, or are due to changes in the gut environment that result from inflammatory reactions and extensive tissue destruction. Despite the involvement of microorganisms in inflammatory processes, antibiotic therapy has generally been unsuccessful in IBD. However, recent studies involving the use of probiotics, prebiotics and synbiotics suggest that there is potential for controlling these diseases through manipulation of the composition of the gut microbiota, and direct interactions with the gut immune system.
Export Options
About this article
Cite this article as:
Macfarlane T. G., Blackett L. K., Nakayama T., Steed H. and Macfarlane S., The Gut Microbiota in Inflammatory Bowel Disease, Current Pharmaceutical Design 2009; 15 (13) . https://dx.doi.org/10.2174/138161209788168146
DOI https://dx.doi.org/10.2174/138161209788168146 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Programs to Facilitate Tuberculosis Drug Discovery: The Tuberculosis Antimicrobial Acquisition and Coordinating Facility
Infectious Disorders - Drug Targets Histone Deacetylase Inhibitors and Colorectal Cancer: what is new?
Anti-Cancer Agents in Medicinal Chemistry Extracts and Flavonoids of <i>Passiflora</i> Species as Promising Anti-inflammatory and Antioxidant Substances
Current Pharmaceutical Design Nanobiotechnology-based Drug Delivery in Brain Targeting
Current Pharmaceutical Biotechnology Defensin Participation in Innate and Adaptive Immunity
Current Pharmaceutical Design Single Nucleotide Polymorphisms in Colitis-Associated Colorectal Cancer: A Current Overview with Emphasis on the Role of the Associated Genes Products
Current Drug Targets Subject Index To Volume 2
Current Immunology Reviews (Discontinued) Heat Shock Paradox and a New Role of Heat Shock Proteins and their Receptors as Anti-Inflammation Targets
Inflammation & Allergy - Drug Targets (Discontinued) Dihydrofolate Reductase as a Target for Chemotherapy in Parasites
Current Pharmaceutical Design Seq and You Will Find
Current Gene Therapy Multiple Forms of Proteasomes and their Role in Tumor Fate
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Glycan Phosphorylases in Multi-Enzyme Synthetic Processes
Protein & Peptide Letters Tachykinins in the Immune System
Current Drug Targets An Update on JAK Inhibitors
Current Medicinal Chemistry Recombinant Adeno-associated Virus 9-mediated Expression of Kallistatin Suppresses Lung Tumor Growth in Mice
Current Gene Therapy Mechanisms of Corticosteroid Resistance in Severe Asthma and Chronic Obstructive Pulmonary Disease (COPD)
Current Pharmaceutical Design Ontogeny of Human Conjugating Enzymes
Drug Metabolism Letters Multidetector Computed Tomography of Iatrogenic Urinary Trauma - Pictorial Review
Current Medical Imaging EGFR(s) in Aging and Carcinogenesis of the Gastrointestinal Tract
Current Protein & Peptide Science Embryonic Stem Cells: Overcoming the Immunological Barriers to Cell Replacement Therapy
Current Stem Cell Research & Therapy